Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GPCL) with its host receptor Niemann-Pick C1 (NPC1) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.

Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GPCL) with its host receptor Niemann-Pick C1 (NPC1) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.

Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Psendomonas spp., Yersinia spp., en tero pathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.

Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.

Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.

Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Psendomonas spp., Yersinia spp., en tero pathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.

Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.

Abstract: Organic compounds showing the ability to inhibit bacterial omptin proteases, specifically Yersinia pestis plasminogen activator (Pla) are disclosed. The disclosed Y. pestis plasminogen activator inhibitor compounds are useful for treating, preventing, or reducing the spread of infections by Y. pestis.

Abstract: A Raman scattering spectrographic analyzer wherein a microscope objective is adapted to view single bio-specimens on a substrate having monodispersed-sized metal particles. A defined wavelength of radiation is applied through the microscope and returning radiation resulting from Raman scattering by bio-specimens is applied to a spectrometer operative to provide a signal corresponding to the wavelength components in said Raman scattered or shifted radiation. The spread spectrum of the Raman shift is analyzed for identification of a bio-specimen.

Abstract: A Raman scattering spectrographic analyzer wherein a microscope objective is adapted to view single bio-specimens on a substrate having monodispersed-sized metal particles. A defined wavelength of radiation is applied through the microscope and returning radiation resulting from Raman scattering by bio-specimens is applied to a spectrometer operative to provide a signal corresponding to the wavelength components in said Raman scattered or shifted radiation. The spread spectrum of the Raman shift is analyzed for identification of a bio-specimen.

Abstract: Recombinant or substantially pure preparations of H. pylori polypeptides are described. The nucleic acids encoding the polypeptides also are described. The H. pylori polypeptides are useful for diagnostics and vaccine compositions.

Abstract: The invention relates to methods and systems of determining targets of compounds and compositions, as well as a high through-put method of screening antimicrobial agents. The methods involve (i) the prediction of a target using two and preferably at least three different submethods, (ii) identifying the gene encoding the target by each of these submethods, (iii) analysing the potential targets of each submethod to predict the putative target, and (iv) validating the target and the drug which perturbs it.

Abstract: Living cells containing genetic material derived from recombinant DNA material and capable of expressing rennin, pre-prorennin and prorennin. The rennin, pre-prorennin and prorennin are derived from cells which are themselves or have had parents thereof treated by recombinant DNA methods to allow production of the desired enzymatic proteins during growth in culture.

Abstract: Living cells containing genetic material derived from recombinant DNA material and capable of expressing rennin, pre-prorennin and prorennin. The rennin, pre-prorennin and prorennin are derived from cells which are themselves or have had parents thereof treated by recombinant DNA methods to allow production of the desired enzymatic proteins during growth in culture.

Abstract: A DNA segment contains a GAL1 promoter of Saccharomyces cerevisae linked to a gene other than the galoctokinase gene, for directing the expression of the gene within a yeast cell.A GAL1 promoter portion of Saccharomyces cerevisae is linked to a foreign DNA segment for use in expressing a desired protein. Yeast cells containing the GAL1 promoter linked to a foreign DNA segment are grown in a medium containing glucose, wherein the yeast cells metabolize the glucose and are permitted to express a polypeptide when galactose is present in the medium.

Abstract: Living cells containing genetic material derived from recombinant DNA material and capable of expressing rennin, pre-prorennin and prorennin. The rennin, pre-prorennin and prorennin are derived from cells which are themselves or have had parents thereof treated by recombinant DNA methods to allow production of the desired enzymatic proteins during growth in culture.

Abstract: A DNA segment containing a GAL1 promoter linked to a gene other than the galactokinase gene for directing the expression of the gene within a yeast cell.